What is SLU-PP-332?
6 min read · Updated October 2026 · MY PEPTIDES Research Team
Key facts
SLU-PP-332 is a small synthetic molecule developed in academic medicinal chemistry at Saint Louis University, which is where the "SLU" in its code name comes from. It is not a peptide and contains no amino acids, despite being sold alongside research peptides and frequently listed in peptide catalogues. In preclinical research it is studied as an agonist of the estrogen-related receptors, a family of nuclear receptors written ERRa, ERRb and ERRg that regulate the transcription of genes involved in mitochondrial biogenesis and oxidative metabolism. Published work in rodent models has reported changes in exercise-related and metabolic measures in those models. The compound is early-stage: it has not entered clinical development, holds no marketing authorisation anywhere, and the literature on it is small and largely from the group that created it. MY PEPTIDES does not stock it. General information for laboratory context only, not medical advice.
The short answer
SLU-PP-332, also written SLU PP 332 and SLUPP332, is a small synthetic molecule from academic medicinal chemistry. It is not a peptide and has no amino acids in it. The "SLU" is Saint Louis University, where it was made; the rest is a compound-series number.
In preclinical research it is studied as an agonist of the estrogen-related receptors, a family of nuclear receptors involved in mitochondrial biogenesis and oxidative metabolism. The literature on it is small, recent, and mostly from the group that created it.
The receptors it acts on, and the naming trap
The estrogen-related receptors, written ERRa, ERRb and ERRg, are among the more badly named things in molecular biology. They are not estrogen receptors and estrogen does not activate them. They were named for resembling the estrogen receptors in sequence, and the name has caused confusion ever since.
What they actually do is regulate transcription. They sit in the nuclear receptor family and influence the expression of genes involved in mitochondrial biogenesis and oxidative metabolism, which is to say genes governing how many mitochondria a cell builds and how it handles fuel. That makes them an obvious target for anyone interested in metabolic regulation at the transcriptional level, and it is the reason a selective agonist is a useful laboratory tool.
A consequence worth noting: because these receptors act on gene expression, their effects unfold over hours and days rather than seconds. That is a different experimental timescale from receptor work on, say, a membrane receptor, and it shapes how studies with this compound are designed.
What the preclinical work reports
Published rodent studies have reported changes in exercise-related and metabolic measures in the models used. That summary is deliberately dry, because the compound has attracted a certain amount of excitable coverage that the underlying evidence does not carry.
Three things are worth being straight about.
The literature is small. This is a recent compound with a limited number of published studies, and much of that work comes from the laboratory that developed it. Independent replication is how a finding earns confidence, and that process has barely begun here.
It has not entered clinical development. Not an unsuccessful trial, not an ongoing one: no clinical programme at all. Every statement about this molecule is a statement about cells and rodents.
And rodent metabolic findings translate poorly. Metabolism is one of the areas where the gap between a mouse model and a human outcome is widest, and the field has a long history of compounds that reshaped mouse physiology and did nothing useful beyond it.
None of that makes the compound uninteresting as a research tool. It makes it an early-stage research tool, which is a different thing from a promising therapy.
Documentation, and why it is harder here
For a compound like this the documentation question is sharper than usual, and for a specific reason: it is a small molecule circulating in a market organised around peptides.
The purity conventions differ. The familiar HPLC purity figure quoted across peptide catalogues is reported against a target-peptide peak and means something specific. A small molecule is characterised by different methods and a bare percentage transferred from peptide convention onto it is not self-explanatory. If you are assessing a certificate for this compound, the questions worth asking are which analytical method produced the figure, and whether the document identifies the material or merely asserts a number. Our guide on certificates of analysis covers the general principles.
There is also no body of independent reference data to check a supplier against, which there would be for an established compound. That absence is the real risk with anything this new.
Where MY PEPTIDES stands
We do not stock the compounds described above. There are no Certificates of Analysis for them in our library and no product pages for them on this site, and this guide is not an offer to supply them. If that changes it will change by a product appearing in the catalogue with a batch certificate attached, not by a line in a guide.
What we do supply, and the documentation standard we hold it to, is set out in our guide on certificates of analysis.
The bottom line
SLU-PP-332 is an early-stage synthetic small molecule, not a peptide, studied in a small preclinical literature as an agonist of the estrogen-related receptors. The evidence is rodent and in-vitro, largely unreplicated, with no clinical development behind it. We do not supply it.
All compounds referenced on this site are discussed strictly in the context of in-vitro laboratory research. Nothing here is a medicine, a supplement or a therapeutic product, nothing here describes administration to humans or animals, and this guide is general information rather than medical, legal or research advice.
Frequently asked questions
- Is SLU-PP-332 a peptide?
- No. It is a small synthetic organic molecule with no amino acids and no peptide bonds. It appears in peptide catalogues because of how this market is organised commercially, not because of its chemistry. If you are evaluating documentation for it, the relevant conventions are those for small molecules rather than those for peptides, which affects what a purity figure on a certificate actually means.
- What does the name SLU-PP-332 mean?
- It is a laboratory code rather than a description. "SLU" refers to Saint Louis University, where the compound was developed, and the rest is an internal compound-series number. Unlike a systematic chemical name it tells you nothing about the structure, which is normal for compounds still at the academic research stage. The variant spellings SLU PP 332 and SLUPP332 refer to exactly the same molecule.
- What are the estrogen-related receptors?
- They are a family of three nuclear receptors, written ERRa, ERRb and ERRg. Despite the name they are not activated by estrogen; they are so called because they resemble the estrogen receptors in sequence. Their documented role is in regulating transcription of genes involved in mitochondrial biogenesis and oxidative metabolism, which is why a compound that activates them is of interest in metabolic research.
- What is SLU-PP-332 studied for in research?
- It is used in preclinical work as a tool for activating the ERR family and observing what follows. Published rodent studies have reported changes in exercise-related and metabolic measures in the models examined. These are findings in specific animal models at specific concentrations and exposures, and they are not established effects in humans.
- How strong is the evidence base?
- It is small and early. The published literature comes largely from the group that developed the compound, it has not been through the independent replication that builds confidence in a finding, and the compound has not entered clinical development at all. That is a meaningfully weaker evidence position than for compounds with a broad independent literature, and it is worth weighing when reading claims about it.
- Do you sell SLU-PP-332?
- No. We do not stock it and there is no Certificate of Analysis for it in our library. It is documented here because it draws search interest under three different spellings and the available information is almost entirely product copy.